In a report released on November 8, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $43.00. The company’s shares closed ...

WARREN, N.J., Nov. 13, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the ...

16:19 EST PTC Therapeutics (PTCT) sees 2024 revenue $750M-$800M, consensus $734.43M Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever gene therapy approved in the U.S. that is directly ...

The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events ...

WARREN, N.J. (AP) — WARREN, N.J. (AP) — PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $106.7 million in its third quarter. The Warren, New Jersey-based company said it had a loss ...

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.76 per share a year ago. These figures ...

PTC Therapeutics ( (PTCT)) has released its Q3 earnings. Here is a breakdown of the information PTC Therapeutics presented to its investors. PTC Therapeutics, Inc. is a global biopharmaceutical ...